Outcomes after resumption of immune checkpoint inhibitor therapy after high‐grade immune‐mediated hepatitis is a research paper published in Cancer (2020). On theSindex it has a DataRank of 0.598. It has been cited 53 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.598
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: T32 DK00753335
NIDDK NIH HHS
Grant: T32 DK007533
National Institutes of Health
Grant: 5T32DK007533-19
ALIMENTARY TRACT RESEARCH IN HEALTH AND DISEASE
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals